{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["Novel", "therapies", "for", "inflammatory", "bowel", "disease", "."], "sentence": "Novel therapies for inflammatory bowel disease .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["Looking", "back", "at", "successes", "and", "failures", "in", "newer", "approaches", "to", "treating", "IBD", ",", "it", "is", "tempting", "--", "although", "still", "difficult", "--", "to", "draw", "conclusions", "about", "pathogenesis", "."], "sentence": "Looking back at successes and failures in newer approaches to treating IBD , it is tempting -- although still difficult -- to draw conclusions about pathogenesis .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["When", "a", "therapy", "proves", "effective", ",", "do", "clinicians", "truly", "know", "how", "it", "works", "?"], "sentence": "When a therapy proves effective , do clinicians truly know how it works ?", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-10372271.txt", "sent_id": "S4", "tokens": ["Even", "with", "a", "therapy", "as", "specific", "as", "anti-TNF", "antibody", ",", "it", "is", "not", "clear", "if", "the", "benefit", "is", "attributable", "to", "simple", "binding", "and", "clearance", "of", "TNF-alpha", "or", "to", "binding", "on", "the", "cell", "surface", "and", "subsequent", "deletion", "of", "the", "activated", "macrophage", "."], "sentence": "Even with a therapy as specific as anti-TNF antibody , it is not clear if the benefit is attributable to simple binding and clearance of TNF-alpha or to binding on the cell surface and subsequent deletion of the activated macrophage .", "event_mentions": [{"id": "E1", "event_type": "Binding", "trigger": {"text": "binding", "start": 21, "end": 21}, "arguments": [{"entity_id": "T1", "text": "TNF-alpha", "role": "Theme"}]}], "entity_mentions": [{"id": "T1", "text": "TNF-alpha", "entity_type": "Protein", "start": 25, "end": 25}, {"id": "T4", "text": "binding", "entity_type": "Binding", "start": 21, "end": 21}]}
{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["When", "a", "drug", "appears", "to", "be", "less", "effective", "than", "preclinical", "models", "suggest", ",", "can", "failures", "in", "effectiveness", "from", "delivery", "or", "dosing", "be", "differentiated", "?"], "sentence": "When a drug appears to be less effective than preclinical models suggest , can failures in effectiveness from delivery or dosing be differentiated ?", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-10372271.txt", "sent_id": "S6", "tokens": ["The", "disappointing", "results", "of", "clinical", "trials", "with", "IL-10", "--", "so", "at", "odds", "with", "the", "prediction", "of", "benefit", "from", "animal", "models", "--", "bring", "into", "question", "the", "validity", "of", "those", "models", "as", "well", "as", "the", "soundness", "of", "design", "of", "the", "clinical", "trials", "on", "which", "efficacy", "of", "IL-10", "is", "judged", "."], "sentence": "The disappointing results of clinical trials with IL-10 -- so at odds with the prediction of benefit from animal models -- bring into question the validity of those models as well as the soundness of design of the clinical trials on which efficacy of IL-10 is judged .", "event_mentions": [], "entity_mentions": [{"id": "T2", "text": "IL-10", "entity_type": "Protein", "start": 7, "end": 7}, {"id": "T3", "text": "IL-10", "entity_type": "Protein", "start": 44, "end": 44}]}
{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["The", "variability", "of", "response", "even", "to", "the", "most", "narrowly", "targeted", "agents", "suggests", "that", "these", "diseases", "are", "far", "more", "heterogeneous", "in", "humans", "than", "in", "their", "murine", "counterparts", "."], "sentence": "The variability of response even to the most narrowly targeted agents suggests that these diseases are far more heterogeneous in humans than in their murine counterparts .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["Clinicians", "are", "only", "just", "beginning", "to", "recognize", "subclinical", "markers", "of", "response", ",", "and", "it", "may", "soon", "be", "possible", "to", "predict", "response", "on", "the", "basis", "of", "genetic", "composition", "."], "sentence": "Clinicians are only just beginning to recognize subclinical markers of response , and it may soon be possible to predict response on the basis of genetic composition .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["For", "the", "moment", ",", "however", ",", "the", "field", "of", "pharmacogenetics", "is", "embryonic", "."], "sentence": "For the moment , however , the field of pharmacogenetics is embryonic .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["Challenges", "in", "developing", "new", "therapeutic", "strategies", "include", "not", "only", "identifying", "novel", "agents", ",", "but", "also", "improving", "the", "definitions", "of", "clinical", "endpoints", "and", "defining", "efficacy", "at", "the", "biologic", "level", "."], "sentence": "Challenges in developing new therapeutic strategies include not only identifying novel agents , but also improving the definitions of clinical endpoints and defining efficacy at the biologic level .", "event_mentions": [], "entity_mentions": []}
{"doc_id": "PMID-10372271.txt", "sent_id": "", "tokens": ["Only", "through", "considered", "evaluation", "of", "clinical", "evidence", "may", "clinicians", "determine", "which", "therapies", "should", "remain", "novelties", "and", "which", "should", "become", "an", "accepted", "part", "of", "the", "armamentarium", "."], "sentence": "Only through considered evaluation of clinical evidence may clinicians determine which therapies should remain novelties and which should become an accepted part of the armamentarium .", "event_mentions": [], "entity_mentions": []}
